albumin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-22 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Elemental bromine (Br2) is toxic and causes chemical burns on human flesh. Inhaling bromine gas results in similar irritation of the respiratory tract, causing coughing, choking, shortness of breath, and death if inhaled in large enough amounts. Chronic exposure may lead to frequent bronchial infections and a general deterioration of health. As a strong oxidising agent, bromine is incompatible with most organic and inorganic compounds. Caution is required when transporting bromine; it is commonly carried in steel tanks lined with lead, supported by strong metal frames. The Occupational Safety and Health Administration (OSHA) of the United States has set a permissible exposure limit (PEL) for bromine at a time-weighted average (TWA) of 0.1 ppm. The National Institute for Occupational Safety and Health (NIOSH) has set a recommended exposure limit (REL) of TWA 0.1 ppm and a short-term limit of 0.3 ppm. The exposure to bromine immediately dangerous to life and health (IDLH) is 3 ppm. Bromine is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U.S. Emergency Planning and Community Right-to-Know Act (42 U.S.C. 11002), and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities.
As a particle moves toward the pole opposite of its charge it moves through the changing pH gradient until it reaches a point in which the pH of that molecule's isoelectric point is reached. At this point the molecule no longer has a net electric charge (due to the protonation or deprotonation of the associated functional groups) and as such will not proceed any further within the gel. The gradient is established before adding the particles of interest by first subjecting a solution of small molecules such as polyampholytes with varying pI values to electrophoresis. The method is applied particularly often in the study of proteins, which separate based on their relative content of acidic and basic residues, whose value is represented by the pI. Proteins are introduced into an immobilized pH gradient gel composed of polyacrylamide, starch, or agarose where a pH gradient has been established. Gels with large pores are usually used in this process to eliminate any "sieving" effects, or artifacts in the pI caused by differing migration rates for proteins of differing sizes. Isoelectric focusing can resolve proteins that differ in pI value by as little as 0.01. Isoelectric focusing is the first step in two-dimensional gel electrophoresis, in which proteins are first separated by their pI value and then further separated by molecular weight through SDS-PAGE. Isoelectric focusing, on the other hand, is the only step in preparative native PAGE at constant pH.
Abortion access was a key topic during the campaign; it was on the ballot in up to 10 states in 2024, including the swing states of Arizona and Nevada. Abortion was a key issue for many voters in the 2022 elections. The issue continued to motivate voters in 2024 along with "the future of democracy in this country" and "high prices for gas, groceries and other goods." According to AP VoteCast, 25% of voters ranked abortion policy as the single most important factor in their vote, similar to the share who in 2022 said that the Supreme Court overturning Roe v. Wade was important to their vote. Of the states where abortion was on the ballot, measures seeking to expand or protect abortion access failed in Florida, South Dakota and Nebraska. Some pundits argued abortion rights referendums could help Harris in November. Democrats predominantly advocate for abortion access as a right, while Republicans generally favor significantly restricting the legality of abortion. Since becoming the presumptive nominee, Harris indicated her support for passing legislation which would restore the federal abortion right protections previously guaranteed by Roe. She argued Trump would let his anti-abortion allies implement Project 2025 proposals to restrict abortion and contraception throughout the United States. Trump claimed credit for overturning Roe but criticized Republicans pushing for total abortion bans. Trump said he would leave the issue of abortion for the states to decide but would allow red states to monitor women's pregnancies and prosecute them if they have an abortion.
=== Myomesin 2 === Myomesin 2 (also known as M-protein) is located in the M1 line of the M-band. It is encoded by the MYOM2 gene. There is currently only one known variant of myomesin 2 and it can be found in fast skeletal muscles and adult cardiac muscles. Myomesin 2 has been shown to have an inverse relationship with the expression of EH-myomesin; as cardiac muscles mature, EH-myomesin is downregulated while myomesin 2 is upregulated.
Sources: en.wikipedia.org
The "Cave of the Seafarers" (Höhle der Seereise) is dated by Rhies to the early 5th century CE, based on stylistic analysis. Carbon dates are significantly later, circa 561-637 CE. The cave contained long narrative sequences about various paths to enlightenment. Most of the panels are now in the Dahlem Museum. The content of the paintings in the "Cave of the Seafarers" is clearly derived from Gandharan prototypes. A painter "Rumakama" (, "the one from Rome"), appears in a Sanskrit inscription in the cave. The inscription, scribbled on the right side of the mural, reads:
Some leucocytes migrate into the tissues of the body to take up a permanent residence at that location rather than remaining in the blood. Often these cells have specific names depending upon which tissue they settle in, such as fixed macrophages in the liver, which become known as Kupffer cells. These cells still serve a role in the immune system.
251Cf has a very small calculated critical mass of about 5 kg (11 lb), high lethality, and a relatively short period of toxic environmental irradiation. The low critical mass of californium led to some exaggerated claims about possible uses for the element.
== Awards == Each year, the MMCF confers a series of awards for social service, scholarship, art, and economic initiative. These awards are traditionally presented to residents of Udaipur as well as to individuals from across India. They are named after figures who hold importance in the history of Mewar. These awards are:
(2026) study the composition of the Quaternary small mammal assemblage from the Araras Ravine at the Lajedo de Soledade site (Rio Grande do Norte, Brazil), providing evidence of similarities with extant faunas from open environments in the Caatinga and Cerrado. A study on the late Pleistocene/early Holocene fauna from the Pikimachay Cave (Peru) is published by Yataco et al. (2026), who interpret the studied site as likely to be a giant ground sloth burrow that was also used by carnivores and/or humans. Hullot et al. (2026) propose a standardized methodological framework for the study of enamel histology in fossil taxa, and apply it to the study of enamel histology and growth of molars of toxodont notoungulates Pleurostylodon modicus, Eurygenium pacegnum, Adinotherium ovinum and Nesodon imbricatus. Von Koenigswald (2026) reviews the morphological diversity of incisors and canines in extant and fossil mammals. Wilson et al. (2026) compare the wear of bilophodont teeth in xenungulates, pyrotheres, fossil and modern tapirs and in extant marsupials, and interpret their findings as suggestive of browsing feeding behaviors of xenungulates and fossil tapirs, as well as of variable diets of different members of Pyrotheria. Evidence of preservation of amino acids in tooth enamel of fossil proboscideans, equids and rhinocerotids dating back as far as 48 million years is presented by Gatti et al. (2026). Herrando-Pérez et al.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.